Cadaverine Tartrate

Cadaverine Tartrate

SCHEMBL372570

O=C([O-])C(O)C(O)C(=O)[O-].[Li+].[Li+]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3BCHECHRM1CHRM2CHRM3CHRM4CHRNA3CHRNA4CHRNB2CHRNB4ESR1ESR2GABRA1GABRB1GABRG2GBA1GHSRHRH1HTR1DHTR2AMAOBOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8UGCGrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.47
LMNA P02545 2/20 0.43
CA4 P22748 3/20 0.40
CYP3A4 P08684 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
BLM P54132 1/20 0.35
PMP22 Q01453 1/20 0.35
TP53 P04637 1/20 0.35
CA1 P00915 3/20 0.33
FAHD1 Q6P587 1/20 0.33
NFKB1 P19838 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
SLC22A6 Q4U2R8 1/20 0.32
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cadaverine Tartrate SCHEMBL3899056 0.96 TSHR (0.44) TSHRLMNACA4CYP3A4TDP1
Cadaverine Tartrate SCHEMBL11836237 0.96 TSHR (0.44) TSHRLMNACA4CYP3A4TDP1
Cadaverine Tartrate SCHEMBL6227892 0.96 TSHR (0.44) TSHRLMNACA4CYP3A4TDP1
Cadaverine Tartrate SCHEMBL11903623 0.96 TSHR (0.44) TSHRLMNACA4CYP3A4TDP1
Cadaverine Tartrate SCHEMBL1129433 0.96 TSHR (0.44) TSHRLMNACA4CYP3A4TDP1
Cadaverine Tartrate SCHEMBL7201448 0.96 TSHR (0.44) TSHRLMNACA4CYP3A4TDP1
Cadaverine Tartrate SCHEMBL3695831 0.96 LMNA (0.48) TSHRLMNACA4CYP3A4TDP1
Cadaverine Tartrate SCHEMBL11147445 0.96 TSHR (0.44) TSHRLMNACA4CYP3A4TDP1
Cadaverine Tartrate SCHEMBL5026914 0.96 TSHR (0.44) TSHRLMNACA4CYP3A4TDP1
Cadaverine Tartrate SCHEMBL3707555 0.96 TSHR (0.44) TSHRLMNACA4CYP3A4TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122080382-A Isosorbide type polycarbonate and preparation method thereof 2026-05-26 CN claimed
US-20260142172-A1 SECONDARY BATTERY AND POWER CONSUMING APPARATUS CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED (CN) 2026-05-21 US claimed
CN-122029657-A Battery monomer and electricity utilization device 宁德时代新能源科技股份有限公司 2026-05-12 CN claimed
EP-4726802-A1 SECONDARY BATTERY AND ELECTRIC DEVICE Contemporary Amperex Technology Co., Limited (CN) 2026-04-15 EP claimed
US-20260097044-A1 ION PAIR LIQUID CRYSTAL FORMULATIONS FOR LONG-ACTING INJECTABLES OF POORLY SOLUBLE DRUGS FORDOZ PHARMA CORP. (US) 2026-04-09 US claimed
US-20260070797-A1 PREPARATION METHOD AND USE OF FUNCTION TYPE ACTIVE ALUMINOSILICATE FUZHOU UNIVERSITY (CN) 2026-03-12 US claimed
EP-3825278-B1 METHOD FOR PREPARING HIGH-PURITY BISFLUOROSULFONYLIMIDE SALT SHANGHAI ROLECHEM CO LTD (CN) 2025-12-17 EP claimed
CN-120149759-A Battery cell, battery device and electricity utilization device 宁德时代新能源科技股份有限公司 2025-06-13 CN claimed
CN-120149508-A Secondary battery and electricity utilization device 宁德时代新能源科技股份有限公司 2025-06-13 CN claimed
CN-120127297-A Battery cell, battery device and electricity utilization device 宁德时代新能源科技股份有限公司 2025-06-10 CN claimed
EP-0662727-B1 Nonaqueous secondary battery, positive-electrode active material and process for making the same SHARP KK (JP) 1998-04-01 EP claimed
EP-0794155-A1 Lithium nickel composite oxide, preparation process therefor and application thereof SHARP KABUSHIKI KAISHA (JP) 1997-09-10 EP claimed
US-5520850-A BINDERS AND CONDUCTORS IN MULTILAYER ELEMENTS CHALONER-GILL BENJAMIN (US) 1996-05-28 US claimed
US-5478672-A Nonaqueous secondary battery, positive-electrode active material SHARP KABUSHIKI KAISHA (JP) 1995-12-26 US claimed
EP-0662727-A1 Nonaqueous secondary battery, positive-electrode active material and process for making the same SHARP KABUSHIKI KAISHA (JP) 1995-07-12 EP claimed
US-5399447-A Batteries VALENCE TECHNOLOGY, INC. (US) 1995-03-21 US claimed
US-5338473-A Aqueous mixture of blue cobaltous hydroxide and complex of cobaltous ion and alpha-hydroxy or alpha-amino carboxylic acid MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1994-08-16 US claimed
US-5057299-A Decomposing complex of cobaltous compound with an hydroxide MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1991-10-15 US claimed
US-3994729-A DIALDEHYDES, FIXING WITH THIOSULFATES, ALUMINUM SALT, TARTARIC ACID OR CITRIC ACID FUJI PHOTO FILM CO., LTD. (JA) 1976-11-30 US claimed
US-3956236-A NYLON, POLYESTERS, OR POLYURETHANES ALLIED CHEMICAL CORPORATION (US) 1976-05-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260142172-A1 SECONDARY BATTERY AND POWER CONSUMING APPARATUS VMP1, INO80C, HVCN1 TSHR 2958/4885LMNA 933/4885CA4 640/4885
US-20260070797-A1 PREPARATION METHOD AND USE OF FUNCTION TYPE ACTIVE ALUMINOSILICATE CA2, SOD1, CA3 TSHR 4325/4885LMNA 1887/4885CA4 45/4885
US-20260097044-A1 ION PAIR LIQUID CRYSTAL FORMULATIONS FOR LONG-ACTING INJECTABLES OF POORLY SOLUBLE DRUGS SSB, LTB4R2, THRB TSHR 14/4885LMNA 1173/4885CA4 2442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.